De Novo KRAS G12C-Mutant SCLC: A Case Report

Meridith L Balbach; Rosana Eisenberg; Wade T Iams

doi:10.1016/j.jtocrr.2022.100306

De Novo KRAS G12C-Mutant SCLC: A Case Report

JTO Clin Res Rep. 2022 Mar 19;3(5):100306. doi: 10.1016/j.jtocrr.2022.100306. eCollection 2022 May.

Authors

Meridith L Balbach^{1

2}, Rosana Eisenberg^{3

4}, Wade T Iams^{1

3}

Affiliations

¹ Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
² Vanderbilt University School of Medicine, Nashville, Tennessee.
³ Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
⁴ Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.

Abstract

The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously "undruggable" target. Here, we present the second reported case of de novo KRAS G12C-mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?

Keywords: Case report; KRAS G12C; Small cell lung cancer; Targeted therapy.

Publication types

Case Reports

Grants and funding

K12 CA090625/CA/NCI NIH HHS/United States